Comparative Pharmacology
Head-to-head clinical analysis: CHROMITOPE SODIUM versus NEPHROFLOW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMITOPE SODIUM versus NEPHROFLOW.
CHROMITOPE SODIUM vs NEPHROFLOW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
None Documented
None Documented
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical